Ex Parte Ozeki et al - Page 3




              Appeal No. 2006-0108                                                                                                             
              Application No. 09/980,620                                                                                                       

                     According to the examiner (Answer, page 4)  Kakuda                                                                        
                     disclose a caffeine stimulation inhibitor and a method for inhibiting caffeine                                            
                     stimulation comprising theanine extracted from tea leaves and/or a                                                        
                     substance having theanine as its main active ingredient …  The                                                            
                     composition is taught to be particularly useful for people who are                                                        
                     hypersensitive to caffeine and/or desire to suppress the action of caffeine                                               
                     (including those who desire to drink tea and coffee without impairing                                                     
                     sleep) to allow them to consume caffeine-containing beverages or foods                                                    
                     without worry over its effects (col. 2, lines 1-62). Kakuda [ ] disclose that                                             
                     the theanine may be crude or refined theanine and the theanine content in                                                 
                     the caffeine stimulation inhibitor is preferably 10 to no more than 500                                                   
                     times the amount of caffeine ingested (col. 2, lines 47-51). The caffeine                                                 
                     stimulation inhibitor is preferably used as an additive of beverages and                                                  
                     foods and may also be absorbed in the form of tablets, capsules, granules                                                 
                     or syrup (col. 2, lines 63-67).  Kakuda discloses a method for inhibiting                                                 
                     caffeine stimulation wherein the caffeine stimulation inhibitor is also in                                                
                     powder and liquid form (claims 2 and 4).                                                                                  
                     We agree that the examiner has provided evidence to support a prima facie case                                            
              of anticipation of claims 1-3.  We begin, as did the examiner (Answer, page 7), with                                             
              claim interpretation.  "If the claim preamble, when read in the context of the entire claim,                                     
              recites limitations of the claim, or, if the claim preamble is 'necessary to give life,                                          
              meaning, and vitality' to the claim, then the claim preamble should be construed as if in                                        
              the balance of the claim. . . .  If, however, the body of the claim fully and intrinsically                                      
              sets forth the complete invention, including all of its limitations, and the preamble offers                                     
              no distinct definition of any of the claimed invention's limitations, but rather merely                                          
              states, for example, the purpose or intended use of the invention, then the preamble is                                          
              of no significance to claim construction because it cannot be said to constitute or                                              
              explain a claim limitation."  Pitney Bowes Inc. v. Hewlett Packard Co., 182 F.3d 1298,                                           
              1305, 51 USPQ2d 1161, 1165-66 (Fed. Cir. 1999).  Thus a claim preamble does not                                                  

                                                           3                                                                                   













Page:  Previous  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  Next 

Last modified: November 3, 2007